Original language | English |
---|---|
Number of pages | 2 |
Journal | Journal of Clinical Oncology |
Volume | 39 |
Issue number | 15 |
DOIs | |
Publication status | Published - 20 May 2021 |
AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
Sophia Frentzas, Tarek Meniawy, Steven Chuan-Hao Kao, Ruihua Wang, Yunxia Zuo, Hao Zheng, Wei Tan
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review